Papers
3
Total Citations
78
H-Index
3
About
Theo M. de Reijke is a leading urological oncologist whose research focuses on advancing minimally invasive, focal therapies for prostate cancer. His major contributions center on evaluating novel ablative techniques—specifically irreversible electroporation (IRE) and focal laser ablation (FLA)—as alternatives to radical surgery. In a pivotal 2018 study (40 citations), he demonstrated that focal IRE offers superior short-term quality-of-life outcomes compared to robot-assisted radical prostatectomy, while maintaining early oncological control. De Reijke further advanced the field through multicenter pilot work on Soractelite transperineal FLA (24 citations), establishing its safety and feasibility, and showing reduced treatment-related morbidity. His 2023 study (14 citations) provided critical dosimetry data, using MRI and contrast-enhanced ultrasound to reliably visualize three-dimensional ablation zones. By systematically proving that focal therapies can preserve continence and erectile function without compromising cancer control, de Reijke has helped shift the paradigm toward organ-sparing treatment. His work is essential reading for researchers and clinicians seeking evidence-based, patient-centered alternatives to whole-gland therapy in localized prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3